AMENDMENT NO. 1Loan Agreement • June 27th, 2019 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (this “Amendment”) is made as of December 25, 2018 by and among Takeda Pharmaceutical Company Limited, a joint-stock company organized and existing under the laws of Japan, (the “Company”) and Japan Bank for International Cooperation (“JBIC”), under that certain Loan Agreement dated as of December 3, 2018 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Loan Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Loan Agreement.
AMENDMENT NO. 1 Dated as of December 20, 2018 to TERM LOAN CREDIT AGREEMENTTerm Loan Credit Agreement • June 27th, 2019 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations • New York
THIS AMENDMENT NO. 1 (this “Amendment”) is made as of December 20, 2018 by and among Takeda Pharmaceutical Company Limited, a joint-stock company organized and existing under the laws of Japan, (the “Company”), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent”), under that certain Term Loan Credit Agreement dated as of June 8, 2018 by and among the Company, the Lenders and the Administrative Agent (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement.
BAXALTA INCORPORATED, as Issuer, SHIRE PLC, as Guarantor TAKEDA PHARMACEUTICAL COMPANY LIMITED as Guarantor, and THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee THIRD SUPPLEMENTAL INDENTURE DATED as of February 4, 2019 TO THE INDENTURE...Third Supplemental Indenture • June 27th, 2019 • Takeda Pharmaceutical Co LTD • Pharmaceutical preparations • New York
Third Supplemental Indenture (this “Third Supplemental Indenture”), dated as of February 4, 2019, among Takeda Pharmaceutical Company Limited, a Japanese joint stock corporation (“Takeda”), Shire plc, a Jersey public company (“Shire”), Baxalta Incorporated, a Delaware corporation (the “Company”), and The Bank of New York Mellon Trust Company, N.A., as trustee under the Indenture referred to below (the “Trustee”).
